JPubb Most Popular Press Releases (Takeda Pharmaceutical Company Limited) http://www.jpubb.com Most Popular Press Releases in JPubb Wed, 22 May 2013 05:23:04 +0900 360 Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain AmyloidosisInvestigational MLN9708: first oral proteasome inhibitor in amyloidosis [Takeda Pharmaceutical Company Limited] http://www.jpubb.com/en/press/60101/ Tue, 11 Dec 2012 15:00:00 +0900 Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Hodgkin Lymphoma at ASH Annual Meeting– Safety and Response Data Support Currently Enrolling Phase III Trial　Evaluating ADCETRIS plus AVD Chemotherapy in Patients with Newly Diagnosed Hodgkin L... [Takeda Pharmaceutical Company Limited] http://www.jpubb.com/en/press/60100/ Tue, 11 Dec 2012 15:00:00 +0900 Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma [Takeda Pharmaceutical Company Limited] http://www.jpubb.com/en/press/60062/ Mon, 10 Dec 2012 15:00:00 +0900 Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas−Safety and Response Data Support Planned Phase III Trial in Front-line MTCL, Including Systemic Anaplastic Large Cell Lymphoma and Other Types of Peripheral T-cell Lymphomas ... [Takeda Pharmaceutical Company Limited] http://www.jpubb.com/en/press/60061/ Mon, 10 Dec 2012 15:00:00 +0900 Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 studyMLN9708: First oral proteasome inhibitor to enter clinical evaluation in front-line multiple myeloma in combination with lenalidomide, dexamethasone [Takeda Pharmaceutical Company Limited] http://www.jpubb.com/en/press/60060/ Mon, 10 Dec 2012 15:00:00 +0900